A carregar...
Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
OBJECTIVE: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin(®). Local tolerability and treatment satisfaction were also assessed. DESIGN:...
Na minha lista:
| Publicado no: | Eur J Endocrinol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Bioscientifica Ltd
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5920019/ https://ncbi.nlm.nih.gov/pubmed/29500310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-17-1073 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|